+39 06 5782665
contact@donawa.com
Italy - UK - USA

COMPANY NEWS

Maria Donawa interviewed by MEDTECH INSIGHT

Donawa Lifescience President, Maria E. Donawa, M.D., has been interviewed by Amanda Maxwell of MEDTECH INSIGHT on the subject of European medical device guidance document MDCG 2024-3 concerning clinical investigation plans in the journal dated 8 April 2024. The guidance, full title ‘Guidance on the content of the clinical investigation plan for clinical investigations of…

Maria Donawa posts article on device clinical evaluation plans on LinkedIn

Donawa Lifescience President, Maria E. Donawa, M.D., has authored a ‘Regulatory Recap’ article on LinkedIn titled ‘CEPs: Parameters vs outcome parameters, what’s the difference?’ The topic arises because of confusion among manufacturers, notified bodies, and competent authorities regarding the interpretation of certain requirements of the EU Medical Device Regulation (MDR, 2017/745) for clinical evaluation plans…

Maria Donawa spoke at the 8th EAAR Annual Conference on 26-27 February 2024

The 8th EAAR Annual Conference on New Medical Device Regulations (RMD2024) took place in Brussels, Belgium, on 26-27 February 2024, featuring speakers from across the MedTech industry, including regulators and notified bodies. Organized by the European Association of Authorised Representatives (EAAR), the conference served as an inclusive platform for all stakeholders across the both medical…

Global News

MHRA publishes ‘Statement of policy intent: international recognition of medical devices’

The UK Medicines and Health products Regulatory Agency (MHRA) has today published its ‘Statement of policy intent: international recognition of medical devices’. This policy is intended to allow medical device manufacturers to use device clearances in other regulatory jurisdictions to ease entry to the GB (England, Scotland, Wales) market by recognising other international regulators’ approvals…

MHRA publishes its strategic approach to AI

The Medicines and Healthcare products Regulatory Agency (MHRA) has set out its strategic approach to artificial intelligence (AI) in a new publication, available from here. Following publication of the UK Government’s white paper ‘A pro-innovation approach to AI regulation’, in 2023, the MHRA reports it has “taken significant steps in the past 12 months to…

FDA issues long-awaited LDT final rule

After years of trying, the US Food and Drug Administration (FDA) has released its plan to bring laboratory developed tests (LDTs) under its regulatory control over the next few years. The much-anticipated final rule amends the agency’s regulations to treat in vitro diagnostic (IVD) tests made by laboratories as medical devices and offers a phased…